Prevents hypokalemia with or without metabolic alkalosis. ANDA 213062, held by Wes Pharma Inc. Potassium Chloride.
As of Nov 15, 2026, ANDA 213062 (Potassium Chloride), held by Wes Pharma Inc, was first approved by FDA on Jun 6, 2022, with 0 approved supplements and 0 published complete response letters.
Potassium Chloride Oral Solution, USP is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 6, 2022 | Original application | Approved | None posted |
| Potassium Chloride20MEQ/15ML · solution;oral | Potassium Chloride | Rx |
| Potassium Chloride40MEQ/15ML · solution;oral | Potassium Chloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
